Please assess the completion status of the following clinical trial:

Trial Title: The Phenylephrine vs. Norepinephrine Infusion Undergoing Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* a healthy singleton pregnancy scheduled for elective cesarean delivery (CD) under combined spinal-epidural anesthesia (CSEA),~* American Society of Anesthesiologists (ASA) physical status I/II~* 20 to 40 years old~Exclusion Criteria:~* history of mental disorder or epilepsy,~* tricyclic or imipramine antidepressant use,~* central nervous system (CNS) disease,~* preexisting or pregnancy-induced hypertension,~* lumbar injury,~* severe hypovolemia,~* allergy~* history of hypersensitivity to vasopressor~* body mass index (BMI) \>40 kg/m2,~* infection at the puncture site

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 Elements (Type: EXPERIMENTAL): Continuously infusion of 0.05ug/kg/min Norepinephrine during the Cesarean Section operation
- Group 2 Elements (Type: EXPERIMENTAL): Continuously infusion of 0.25ug/kg/min phenylephrine during the Cesarean Section operation
- Group 3 Elements (Type: PLACEBO_COMPARATOR): In the placebo-control group, 3 ml/kg/min of LR was administrated according to standard weight.

Based on this trial design, predict the completion outcome and termination type (if applicable).